[go: up one dir, main page]

MX2022013152A - Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias. - Google Patents

Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.

Info

Publication number
MX2022013152A
MX2022013152A MX2022013152A MX2022013152A MX2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A
Authority
MX
Mexico
Prior art keywords
compositions
preventing
controlling
methods
mycobacterial infections
Prior art date
Application number
MX2022013152A
Other languages
English (en)
Inventor
Andrew Potter
Antonio Facciuolo
Philip Griebel
Neil Rawlyk
Jeffrey Chen
Elodie Pastural
Manjeet Bains
Michael Trimble
Amy Lee
Robert Hancock
Volker Gerdts
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of MX2022013152A publication Critical patent/MX2022013152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen antígenos de micobacterias, como MAP y antígenos de M. bovis; los antígenos se pueden usar en composiciones de subunidades para provocar respuestas inmunes para prevenir y/o controlar infecciones micobacterianas, así como en diagnósticos para detectar mamíferos infectados con micobacterias.
MX2022013152A 2020-04-20 2021-04-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias. MX2022013152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012668P 2020-04-20 2020-04-20
PCT/CA2021/050527 WO2021212215A1 (en) 2020-04-20 2021-04-19 Compositions and methods for preventing, controlling and diagnosing mycobacterial infections

Publications (1)

Publication Number Publication Date
MX2022013152A true MX2022013152A (es) 2023-02-09

Family

ID=78270853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013152A MX2022013152A (es) 2020-04-20 2021-04-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.

Country Status (8)

Country Link
US (1) US20230218734A1 (es)
EP (1) EP4138894A4 (es)
AU (1) AU2021258911A1 (es)
BR (1) BR112022021258A2 (es)
CA (1) CA3176303A1 (es)
CL (1) CL2022002893A1 (es)
MX (1) MX2022013152A (es)
WO (1) WO2021212215A1 (es)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5985354A (en) 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5053451A (en) 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5855895A (en) 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5807757A (en) 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU740545B2 (en) * 1997-04-02 2001-11-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
NZ504951A (en) * 1997-11-10 2001-06-29 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US6207171B1 (en) 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
WO2007108829A2 (en) * 2005-10-26 2007-09-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US7846420B2 (en) * 2007-04-23 2010-12-07 Greenstein Robert J Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same
EP2336332A3 (en) * 2008-04-29 2011-11-09 Monsanto Technology LLC Genes and uses for plant enhancement
AU2009304552B2 (en) 2008-10-16 2015-02-19 Dalhousie University Combination adjuvant formulation
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection
US11591375B2 (en) * 2018-01-22 2023-02-28 Oregon State University Immunogenic compositions comprising Mycobacterium bovis surface proteins and uses thereof
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗

Also Published As

Publication number Publication date
AU2021258911A1 (en) 2022-11-24
US20230218734A1 (en) 2023-07-13
WO2021212215A1 (en) 2021-10-28
EP4138894A1 (en) 2023-03-01
EP4138894A4 (en) 2024-06-26
CA3176303A1 (en) 2021-10-28
BR112022021258A2 (pt) 2023-01-17
CL2022002893A1 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
Tkachuk et al. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
WO2014063704A8 (en) M. tuberculosis vaccines
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
MX2018014270A (es) Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
PH12020550941A1 (en) Methods and compositions to prevent microbial infection
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
MX2021005026A (es) Analogos de cannabinoides y metodos para su preparacion.
MY173004A (en) Mycobacterial antigen vaccine
Bai et al. Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells
MX2022014984A (es) Atenuacion de virulencia bacteriana mediante atenuacion de transporte de folato bacteriano.
MX393266B (es) Composiciónpara usarse en terapia de microbiota
WO2019113509A3 (en) Methods for enhancing and maintaining car-t cell efficacy
PH12018501822A1 (en) Immune development accelerator
MX2022013152A (es) Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.
AR094296A1 (es) Composicion inmunogenica que comprende antigenos de mycoplasma
WO2020102717A3 (en) Clostridium difficile multi-component vaccine
EA202190876A1 (ru) Композиции, содержащие бактериальные штаммы
Rao et al. Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype
WO2019027224A3 (ko) 결핵균 독소-항독소 체계를 표적으로 하는 펩타이드 및 이의 용도
CY1107538T1 (el) Εμβολιο μυκοπλασματος αδρανοποιημενο με σαπωνινη
MY193450A (en) Obtaining high-performance yeast strains for metabolizing arabinose
Tirado et al. Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis
MX2021007599A (es) Composiciones probióticas listas para utilizar y usos de las mismas.
BR112021024655A2 (pt) Reagente de diagnóstico
WO2020023949A3 (en) Predictive biomarkers for an immune response